Correction: CircEAF2 counteracts Epstein-Barr viruspositive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Following the publication of the original article [1], the authors noticed a similarity in the DAPI staining and merge images between the Untreated_Farage-circEAF2 (FC-U) group and the Epirubicin_Farage-vector (FCV-E) group in Figure 6B.After a thorough re-examination of the original data, authors found the problem might have happened in the data acquisition.They took several pictures for each sample, but due to the similar compose type of file names, might mislabeled the No.1 of Farage-circEAF2 in untreated group (noted as FC-U#1) as No.1 of Farage-vector in Epirubicin group (noted as FCV-E#1), resulting in other yield of picture of FC-U cells was mistakenly reused as FCV-E cells.These errors have been corrected in the revised Fig. 6B as shown below.